Polymorphism at the Sp 1 Binding Site in the Collagen Type I α 1 Gene Does Not Predict Bone Mineral Density in Postmenopausal Women in Sweden

1998 ◽  
Vol 63 (4) ◽  
pp. 293-295 ◽  
Author(s):  
M. Lidén ◽  
B. Wilén ◽  
S. Ljunghall ◽  
H. Melhus
Keyword(s):  
Bone Mineral Density ◽  
Binding Site ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Collagen Type ◽  
Collagen Type I ◽  
Type I ◽  
Mineral Density

scholarly journals Collagen Type I alpha1 (COL1A1) Gene Polymorphism and Bone Mineral Density in Postmenopausal Kazakh Women

2014 ◽  
Vol 3 ◽  
Author(s):  
Akbota Aitkulova ◽  
Ainur Akilzhanova ◽  
Zhannur Abilova ◽  
Zaida Zhumatova ◽  
Gulbanu Akilzhanova ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Gene Polymorphism ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Genomic Dna ◽  
Collagen Type ◽  
Collagen Type I ◽  
Type I ◽  
Mineral Density ◽  
Col1a1 Gene

Introduction: Single nucleotide polymorphism (SNP) at the collagen type I alpha 1 gene (COL1A1) rs1800012 has been widely studied and has shown an association with bone mineral density (BMD) and fractures. A minor allele TT of this SNP was found to be greatly overrepresented in individuals with fractures compared to controls, thus becoming a good predictor of  increased fracture risk. The aim of this investigation was to evaluate potential association between COL1A1 gene polymorphism and osteoporosis in Kazakh postmenopausal women.Methods: The study population included 103 postmenopausal women recruited from Pavlodar and Almaty clinics. BMD was measured using DEXA. Genomic DNA was extracted from peripheral venous blood of study participants with Wizard® Genomic DNA Purification Kit (Promega, USA). Detection of COL1A1 +1245G/T (Sp1) polymorphism was done by the TaqMan® SNP Genotyping Assay of real-time PCR.Results: Densitometry results revealed 36 osteoporotic, 42 osteopenic, and 25 normal postmenopausal women. Data analysis of 1245G>T polymorphism in COL1A1 gene in the group of women with osteopenia and osteoporosis revealed deviation from Hardy-Weinberg equilibrium. The mutant TT genotype was prevalent compared to the heterozygous genotype GT in both groups. Distributions were 83% GG, 3% GT, and 14% TT in the group with osteopenia and 80% GG, 6% GT, and 14% TT in the group with osteoporosis. The distribution of genotypes frequency in the group of normal postmenopausal women was 76% GG, 16% GT, and 8% TT.Conclusion: These results suggest that TT genotype of COL1A1 +1245G/T (Sp1) polymorphism is associated with risk of postmenopausal osteoporosis in Kazakh women. Further studies involving a larger number of women are needed to clarify the relationship of this polymorphism with risk of osteoporosis. 

Association of Collagen Type I α1 Gene Polymorphism with Bone Mineral Density in Osteoporotic Women in Serbia

2010 ◽  
Vol 19 (7) ◽  
pp. 1299-1303 ◽  
Author(s):  
Katarina Trajkovic ◽  
Milka Perovic ◽  
Aleksej Tarasjev ◽  
Nada Pilipovic ◽  
Vera Popovic ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Gene Polymorphism ◽  
Bone Mineral ◽  
Collagen Type ◽  
Collagen Type I ◽  
Type I ◽  
Mineral Density

scholarly journals Denosumab in transfusion-dependent thalassemia osteoporosis: a randomized, placebo-controlled, double-blind phase 2b clinical trial

2018 ◽  
Vol 2 (21) ◽  
pp. 2837-2847 ◽  
Author(s):  
Ersi Voskaridou ◽  
Ioannis Ntanasis-Stathopoulos ◽  
Athanasios Papaefstathiou ◽  
Dimitrios Christoulas ◽  
Maria Dimopoulou ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Collagen Type ◽  
Collagen Type I ◽  
Tartrate Resistant Acid Phosphatase ◽  
Type I ◽  
Mineral Density ◽  
Double Blind ◽  
Bone Specific Alkaline Phosphatase ◽  
Dickkopf 1

Abstract Denosumab (DNM) is a fully human monoclonal antibody against the receptor activator of nuclear factor kappa-B ligand (RANKL) that has been licensed for the treatment of different types of osteoporosis. However, the prospective data for the evaluation of DNM efficacy on transfusion-dependent thalassemia (TDT)–induced osteoporosis are rather limited. Thus, we conducted a randomized, placebo-controlled, double-blind, phase 2b clinical trial to evaluate DNM in TDT osteoporosis. Patients were assigned to receive either 60 mg DNM (n = 32) or placebo (n = 31) subcutaneously on day 0 and 180 during a total of 12 months of follow-up. The percentage increase of L1-L4 bone mineral density was higher in the DNM group than the placebo group (5.92% ± 5.25% vs 2.92% ± 5.56%, respectively; P = .043), whereas the advantage of DNM regarding wrist bone mineral density was much higher compared with placebo (−0.26% ± 5.31% vs −3.92% ± 8.71%, respectively; P = .035). No grade 3 or 4 toxicity was observed. DNM reduced pain scores that remained unaltered in the placebo group. DNM showed a significant reduction of soluble RANKL (sRANKL), sRANKL/osteoprotegerin ratio, C-telopeptide of collagen type I, tartrate-resistant acid phosphatase isoform-5b, and bone-specific alkaline phosphatase between baseline and the 12th month (P < .01 for all comparisons) without changes in dickkopf-1, sclerostin, and osteocalcin. On the contrary, placebo patients showed an increase in sRANKL, osteoprotegerin, dickkopf-1, sclerostin, C-telopeptide of collagen type I, tartrate-resistant acid phosphatase isoform-5b, and bone-specific alkaline phosphatase during the study period (P < .01 for all comparisons). In conclusion, DNM increased lumbar spine and wrist bone mineral density and reduced pain and bone remodeling markers, and thus it is another valuable option for the management of TDT-induced osteoporosis. This trial was registered at www.clinicaltrials.gov as #NCT02559648.

Combined effects of collagen type I alpha1 (COL1A1) Sp1 polymorphism and osteoporosis risk factors on bone mineral density in Turkish postmenopausal women

Gene ◽  
2014 ◽  
Vol 540 (2) ◽  
pp. 226-231 ◽  
Author(s):  
Ozlem Kurt-Sirin ◽  
Hulya Yilmaz-Aydogan ◽  
Mehmet Uyar ◽  
Mehmet-Fatih Seyhan ◽  
Turgay Isbir ◽  
...  
Keyword(s):  
Risk Factors ◽  
Bone Mineral Density ◽  
Postmenopausal Women ◽  
Collagen Type ◽  
Collagen Type I ◽  
Type I ◽  
Combined Effects ◽  
Mineral Density ◽  
Osteoporosis Risk Factors ◽  
Osteoporosis Risk

scholarly journals Collagen type I alpha 1 gene polymorphism in premature ovarian failure

2013 ◽  
Vol 141 (5-6) ◽  
pp. 344-348 ◽  
Author(s):  
Svetlana Vujovic ◽  
Selma Kanazir ◽  
Miomira Ivovic ◽  
Milina Tancic-Gajic ◽  
Milka Perovic ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Gene Polymorphism ◽  
Bone Mineral ◽  
Premature Ovarian Failure ◽  
Collagen Type ◽  
Collagen Type I ◽  
Ovarian Failure ◽  
Type I ◽  
Relative Distribution ◽  
Mineral Density

Introduction. Premature ovarian failure (POF) is characterized by amenorrhea, hypergonadotropism and hypoestrogenism in women bellow 40 years. Osteoporosis is one of the late complications of POF. Objective. To correlate collagen type I alpha1 (COLIA1) gene polymorphism with bone mineral density (BMD) in women with POF. Methods. We determined the COLIA1 genotypes SS, Ss, ss in 66 women with POF. Single nucleotide polymorphism (G to T substitution) within the Sp 1-binding site in the first intron of the COLIA1 gene was assessed by polymerase chain reaction (PCR) followed by single-stranded conformation polymorphism (SSCP) analysis. Bone mineral density (BMD) was measured at the lumbar spine region by dual X-ray absorptiometry. Statistics: Kruskal-Wallis ANOVA, Chisquare test, Spearman correlation test. Results. The relative distribution of COLIA1 genotype alleles was SS - 54.4%, Ss - 41.0% and ss - 4.5%. No significant differences were found between genotype groups in body mass index, age, duration of amenorrhea or BMD. A significant positive correlation was observed between BMI and parity. Conclusion. The COLIA1 gene is just one of many genes influencing bone characteristics. It may act as a marker for differences in bone quantity and quality, bone fragility and accelerated bone loss in older women. However, in young women with POF, COLIA1 cannot identify those at higher risk for osteoporosis.

scholarly journals Anti-osteoporosis effect of Notopterygium incisum Ting ex H. T. Chang extract in rats

2021 ◽  
Vol 18 (10) ◽  
pp. 2051-2055
Author(s):  
Hai Ding ◽  
Wenju Chang ◽  
Jian Yao ◽  
Fendou Liu ◽  
Qingliang Zeng ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Serum Alkaline Phosphatase ◽  
Collagen Type I ◽  
Positive Control ◽  
Type I ◽  
Sprague Dawley ◽  
Mineral Density ◽  
Control Drug ◽  
Bone Trabeculae

Purpose: To investigate the effect of Notopterygium incisum Ting ex H.T. Chang extract (NICE) on ovariectomy-induced osteoporosis in rats. Methods: Female Sprague-Dawley rats were randomly assigned to a normal group (control) and five ovariectomy (OVX) subgroups: OVX with vehicle (OVX), OVX with positive control drug alendronate sodium tablets (1.8 mg/kg/week), and OVX with varying NICE doses (45, 90, or 180 mg/kg/day). After rats were subjected to ovariectomy for 4 weeks, alendronate or NICE were administered orally daily for 16 weeks. The bone mineral density (BMD) of the L4 vertebrae and right femurs of all rats was estimated. The serum hormones estradiol (E2), follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels and serum alkaline phosphatase (ALP), osteocalcin (OC) and telopeptides of collagen type I (CTx) levels of rats were detrmined. Results: The results show that NICE dose-dependently inhibited bone mineral density (BMD) reduction of L4 vertebrae and femurs (p < 0.05). Compared with OVX group, serum E2, FSH and LH levels was significantly increased in osteoporosis rats (p < 0.01), but serum ALP, CTx, and OC concentrations were significantly lower (p < 0.05). On the other hand, bone trabeculae in the three NICE groups and nilestriol group were all wider, while the space and connections increased. Conclusion: These findings indicate that NICE mitigates OVX-induced osteoporosis in rats, and hence can potentially be developed for the management of osteoporosis.

Sign in / Sign up

Export Citation Format

Share Document